Acadia Pharma (ACAD) Tops Q4 EPS by 64c ; Offers Guidance

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.86, $0.64 better than the analyst estimate of $0.22. Revenue for the quarter came in at $259.6 million versus the consensus estimate of $271.64 million.

GUIDANCE:

Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.05 billion.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Deutsche Bank Reiterates Buy Rating on Volkswagen AG (VOW:GR) (VWAGY)
• Rothschild Redburn Starts Z AI Co Ltd (2513:HK) at Buy
• UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy